AIDS research and human retroviruses最新文献_第3页

Sequence Notes: Identification of Two New CRF01_AE/CRF07_BC Recombinants in Men Who Have Sex with Men Populations in Beijing, China. 序列注释：在中国北京男性性行为人群中鉴定出两个新的CRF01_AE/CRF07_BC重组基因。

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-06-01 Epub Date: 2025-04-14 DOI: 10.1089/aid.2024.0098

Miao Yu, Xiaorui Wang, Lei Jia, Jingwan Han, Hanping Li, Xiaolin Wang, Bohan Zhang, Jingyun Li, Yongjian Liu, Hongling Wen, Lin Li

引用次数: 0

Near-Full-Length Genomic Characterization of Two Novel HIV-1 Unique Recombinants (CRF01_AE/CRF07_BC) and (CRF01_AE/CRF68_01B) in Shijiazhuang, Hebei Province, China. 中国河北省石家庄市两个新型 HIV-1 独特重组体 (CRF01_AE/CRF07_BC) 和 (CRF01_AE/CRF68_01B) 的近全长基因组特征。

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-06-01 Epub Date: 2025-02-18 DOI: 10.1089/aid.2024.0114

Lixuan Zhang, Yuxin Feng, Kuiling Shen, Lijing Wang, Yuling Wang, Jianhua Lu, Huixia Gao, Hanping Li, Jingwan Han, Lin Li, Erhei Dai

{"title":"Near-Full-Length Genomic Characterization of Two Novel HIV-1 Unique Recombinants (CRF01_AE/CRF07_BC) and (CRF01_AE/CRF68_01B) in Shijiazhuang, Hebei Province, China.","authors":"Lixuan Zhang, Yuxin Feng, Kuiling Shen, Lijing Wang, Yuling Wang, Jianhua Lu, Huixia Gao, Hanping Li, Jingwan Han, Lin Li, Erhei Dai","doi":"10.1089/aid.2024.0114","DOIUrl":"10.1089/aid.2024.0114","url":null,"abstract":"Heterosexual transmission (HETE) represents the predominant method of transmission for the human immunodeficiency virus type 1 (HIV-1) in Shijiazhuang, Hebei Province, China. The number of circulating recombinant forms (CRFs) and unique recombinant forms (URFs) continues to increase in this region. In the present study, two novel URFs (TFH010919 and TFH010944) were identified, both derived from HETEs in the Shijiazhuang area. The phylogenetic and recombination breakpoint analyses conducted on the near-full-length genomes of the two novel URFs revealed that the CRF01_AE strains serve as the predominant backbones for both TFH010919 and TFH010944. TFH010919 is a second-generation recombinant form composed of CRF01_AE and CRF07_BC, whereas TFH010944 is formed by the combination of CRF01_AE and CRF68_01B. This finding indicates that HIV-1 prevalence among HETEs remains a significant concern, driven by complex sexual networks that facilitate the spread of diverse recombinant strains, providing more opportunities for the recombination of viruses. The emergence of these new URFs revealed the ongoing evolution of HIV-1 and underscores the critical need for continuous monitoring of viral diversity in Hebei Province and surrounding regions to control HIV-1 transmission within the vulnerable population and beyond.","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"305-311"},"PeriodicalIF":1.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Late HIV Diagnosis on Costs of Care in a Public Health Care Setting. 艾滋病毒晚期诊断对公共卫生保健机构护理费用的影响。

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-06-01 Epub Date: 2025-03-19 DOI: 10.1089/aid.2024.0100

Ranjit S Samra, Patricia M Griffiths, Sue J Lee, Emma L Smith, Phillip Rawson-Harris, Jennifer F Hoy, James H McMahon

{"title":"Impact of Late HIV Diagnosis on Costs of Care in a Public Health Care Setting.","authors":"Ranjit S Samra, Patricia M Griffiths, Sue J Lee, Emma L Smith, Phillip Rawson-Harris, Jennifer F Hoy, James H McMahon","doi":"10.1089/aid.2024.0100","DOIUrl":"10.1089/aid.2024.0100","url":null,"abstract":"Despite increased HIV testing and access to treatment in Australia, presentations with advanced disease occur, placing a significant burden on the health system. We sought to describe costs associated with HIV care in the first year post diagnosis in a specialized, tertiary-level HIV service and identify factors predicting increased health care costs. People newly diagnosed with HIV from 2016 to 2020 were included in the study. Data were gathered regarding their demographics (age, gender, birthplace, and first language), HIV parameters (viral load [VL] and CD4 cell count), antiretroviral therapy start date, opportunistic illness history, and health care costs (inpatient, outpatient, and emergency) from 12 months of diagnosis. Multivariable modeling was used to identify factors associated with increased costs. We identified 147 people; median age 38 years, 90% male, median CD4 count at diagnosis 338 cells/µL with median initial cost of care AUD $22,929 (interquartile range $11,902-$39,175). Costs associated with advanced HIV diagnosis (CD4 < 200 cells/µL; n = 52) were more than double an early HIV diagnosis (CD4 ≧ 350 cells/µL; n = 69) (median $46,406 vs. $20,274; p < .001). In univariate analysis, older age, higher VL, low CD4 count, and VL >200 copies/mL after 6 months were associated with increased costs. In multivariate analysis, older age (p = .001) and CD4 count <200 cells/µL (p = .001) were the only factors predicting increased cost in the first year after HIV diagnosis. Prioritizing HIV testing strategies to allow earlier diagnosis of HIV would significantly reduce the financial burden of HIV care.","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"286-291"},"PeriodicalIF":1.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First Characterization of HTLV-1 Complete Genomes from Asymptomatic and Symptomatic Argentinean Patients. 来自阿根廷无症状和有症状患者的HTLV-1全基因组

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-06-01 Epub Date: 2025-03-19 DOI: 10.1089/aid.2024.0068

María Verónica Pineda, Paola Miyazato, Maximiliano Distefano, Benjy Tan Jek Yang, Marcelo Golemba, María Belén Bouzas, Yorifumi Satou, Andrea Mangano

{"title":"First Characterization of HTLV-1 Complete Genomes from Asymptomatic and Symptomatic Argentinean Patients.","authors":"María Verónica Pineda, Paola Miyazato, Maximiliano Distefano, Benjy Tan Jek Yang, Marcelo Golemba, María Belén Bouzas, Yorifumi Satou, Andrea Mangano","doi":"10.1089/aid.2024.0068","DOIUrl":"10.1089/aid.2024.0068","url":null,"abstract":"HTLV-1 is the etiologic agent of adult T-cell leukemia/lymphoma (ATL/ATLL) and is related to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The factors that influence the development of the disease remain unknown. The majority of patients with HTLV-1 infection remain asymptomatic throughout their lives, while 2.5%-5% developed ATLL and 0.3%-2% HAM/TSP. About 10 to 20 million people worldwide are infected with HTLV-1. In Argentina, HTLV-1 infection has been documented particularly in the northeast provinces neighboring Bolivia and Paraguay. This study aims to analyze the nine complete genomes of HTLV-1 from asymptomatic and symptomatic patients using next-generation sequencing. Mutation analysis and identification of viral integration sites were performed. Mutation analysis revealed distinct mutation patterns, identifying clusters associated with patients with HAM/TSP and lymphoma. Multiple integration sites across different chromosomes were found, suggesting random integration without specific hotspots. A defective provirus was identified in a patient with lymphoma, potentially impacting immune evasion and clonal expansion. Complete HTLV-1 genome sequences from circulating strains in Argentina were obtained for the first time. This contributes to the knowledge of the genetic variability of the virus and its integration sites in the human genome and reveals that the nature of the HTLV-1 provirus in natural infection is complex.","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"292-300"},"PeriodicalIF":1.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of INSTI on a Drug-Resistant Mutation (S68S Insertion) in a Patient Infected with HIV-1 CRF06_cpx. INSTI对HIV-1 CRF06_cpx患者耐药突变（S68S插入）的影响

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-06-01 Epub Date: 2025-02-03 DOI: 10.1089/aid.2024.0107

Young-Keol Cho, Jinny Lee

引用次数: 0

Sequence Notes: Characterization of the Near-Full-Length Genome of Two Novel Unique Recombinant Genome (CRF01_AE/CRF79_0107, CRF01_AE/CRF07_BC) in Hebei, China. 序列注释：中国河北两个新的独特重组基因组（CRF01_AE/CRF79_0107, CRF01_AE/CRF07_BC）的近全长基因组鉴定。

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-06-01 Epub Date: 2025-04-10 DOI: 10.1089/aid.2024.0127

Kuiling Shen, Yuxin Feng, Changdong Wang, Jingwan Han, Yongjian Liu, Lei Jia, Bohan Zhang, Xiaolin Wang, Jingyun Li, Ziwei Liu, Erhei Dai, Hanping Li, Lin Li, Huimin Yan

{"title":"Sequence Notes: Characterization of the Near-Full-Length Genome of Two Novel Unique Recombinant Genome (CRF01_AE/CRF79_0107, CRF01_AE/CRF07_BC) in Hebei, China.","authors":"Kuiling Shen, Yuxin Feng, Changdong Wang, Jingwan Han, Yongjian Liu, Lei Jia, Bohan Zhang, Xiaolin Wang, Jingyun Li, Ziwei Liu, Erhei Dai, Hanping Li, Lin Li, Huimin Yan","doi":"10.1089/aid.2024.0127","DOIUrl":"10.1089/aid.2024.0127","url":null,"abstract":"The global fight against human immunodeficiency virus (HIV) is complicated by its extensive genetic diversity, which arises from high mutation rates, rapid replication, and frequent recombination events. These factors lead to the emergence of numerous recombinant forms of HIV-1, contributing to the virus's adaptability and complicating prevention and treatment efforts. In this study, we identified two novel, unique recombinant forms (URFs) of HIV-1, CRF01_AE/CRF79_0107 and CRF01_AE/CRF07_BC, through near full-length genome sequence analysis. These URFs were detected in two individuals within the student men who have sex with men (MSM) population of Shijiazhuang, Hebei Province, China. Both utilized CRF01_AE as the underlying template, and PQ585802 represents a second-generation recombinant form comprising CRF01_AE and CRF79_0107. It is a novel recombinant form that was initially identified. PQ585803 represents a second-generation recombinant form, composed of CRF01_AE and CRF07_BC, and exhibits distinctive characteristics when compared to previously identified recombinant forms. This study underscores the urgent need for targeted public health measures focusing on high-risk populations, such as MSM and students, to curb the spread of HIV-1. Tailored education, enhanced access to prevention services, and strategies addressing risky behaviors are critical in reducing HIV-1 prevalence and mitigating the challenges posed by recombinant forms.","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"317-321"},"PeriodicalIF":1.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic Markers and Immunological Trajectories in a Cohort of Patients with HIV and Hepatitis C Virus Coinfection Treated with Direct-Acting Antivirals. 直接作用抗病毒药物治疗的HIV和丙型肝炎合并感染患者的肝脏标志物和免疫轨迹

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-05-21 DOI: 10.1089/aid.2025.0001

Gina Simoncini, Jun Li, Cynthia Mayer, Lauren F Collins, Linda Battalora, Kate Buchacz

{"title":"Hepatic Markers and Immunological Trajectories in a Cohort of Patients with HIV and Hepatitis C Virus Coinfection Treated with Direct-Acting Antivirals.","authors":"Gina Simoncini, Jun Li, Cynthia Mayer, Lauren F Collins, Linda Battalora, Kate Buchacz","doi":"10.1089/aid.2025.0001","DOIUrl":"https://doi.org/10.1089/aid.2025.0001","url":null,"abstract":"Persons with HIV (PWH) have disproportionate hepatitis C virus (HCV) infection prevalence and liver-related morbidity and mortality. These sequelae may be alleviated by curative direct-acting antiviral (DAA) treatment; however, longitudinal effects of DAAs on clinical biomarkers are not well-characterized. We included PWH enrolled in the HIV Outpatient Study (HOPS) who were prescribed DAAs and DAA-naïve PWH of comparable age, sex, race/ethnicity, and fibrosis-4 (FIB-4) profiles. We contrasted the DAA effect on longitudinal trajectories of immunological and hepatic markers using generalized linear mixed models (GLMM) from 2010 to 2020. Of 347 PWH/HCV coinfection, median age was 53.8 years, 30.5% were women, 67.1% were publicly insured, 44.4% were non-Hispanic Black, and 153 (44.1%) were prescribed DAAs (median follow-up = 3.55 years). In multivariable GLMM analysis, DAA treatment was associated with [mean (95% confidence interval)] faster decline in alanine aminotransferase of -7.86 mu/µL/year (-15.39, -0.33) and faster increase in platelets of 6.99 mu/µL/year (2.89, 11.09). Changes in aspartate aminotransferase were comparable between groups. FIB-4 decreased in the DAA-treated but not the DAA-naïve group: -0.26 (-0.41, -0.11) versus 0.02 (-0.16, 0.20)/year, respectively. There was a faster increase in cluster of differentiation (CD)4 count of 0.05 (0.03-0.08) and CD8 count of 0.04 (0.02-0.07) log cells/mL/year in the DAA-treated compared with the DAA-naïve group (p < .001), but not in the CD4/CD8 ratio (p = .36). Among U.S. PWH/HCV coinfection treated with DAAs, we found modest changes in immunological markers and substantial improvements in hepatic markers modeled over 4 years of DAA treatment. Curative DAA treatment is critical to mitigate advanced liver fibrosis.","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond 2010: Gaps, Challenges, and Priorities for the Future of Preclinical HIV Preexposure Prophylaxis (PrEP): Summary of the October 20-21, 2009 Workshop. 2010 年之后：临床前艾滋病毒预防疗法 (PrEP) 未来的差距、挑战和优先事项：2009 年 10 月 20-21 日研讨会摘要。

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-05-08 DOI: 10.1089/aid.2010.0136

Fulvia Veronese, Jim A Turpin, Cindra Feuer

{"title":"Beyond 2010: Gaps, Challenges, and Priorities for the Future of Preclinical HIV Preexposure Prophylaxis (PrEP): Summary of the October 20-21, 2009 Workshop.","authors":"Fulvia Veronese, Jim A Turpin, Cindra Feuer","doi":"10.1089/aid.2010.0136","DOIUrl":"10.1089/aid.2010.0136","url":null,"abstract":"A workshop entitled Beyond 2010: Gaps, Challenges, and Priorities for the Future of Preclinical HIV Pre-Exposure Prophylaxis (PrEP) was sponsored by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), on October 20-21, 2009, in Bethesda, Maryland. The objective of the workshop was to identify the main gaps in current knowledge, challenges, and priorities for the establishment of a PrEP preclinical pipeline and to also provide guidance for future directions of the field and DAIDS activities in this area. This 2-day workshop, through various presentations and breakout group discussions, specifically addressed four main topics that will be critical in identifying and advancing the next generation of PrEP candidates for clinical testing. The topics were (1) drug discovery, (2) pharmacokinetics (PK) and pharmacodynamics (PD), (3) animal models, and (4) delivery systems for prolonged activity. We report here a summary of the presentations and highlights of salient discussion topics from this workshop.","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40080269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Benefit of a Conservative Treatment for High-Risk Human Papillomavirus Lesions in Patients with HIV. HIV患者高危人乳头瘤病毒病变保守治疗的临床疗效

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-05-01 Epub Date: 2025-01-08 DOI: 10.1089/aid.2024.0067

Jesús Joaquín Hijona Elósegui, Antonio Luis Carballo García, Ana Cristina Fernández Rísquez, Jesús Carlos Presa Lorite, Gabriel Fiol Ruiz

{"title":"Clinical Benefit of a Conservative Treatment for High-Risk Human Papillomavirus Lesions in Patients with HIV.","authors":"Jesús Joaquín Hijona Elósegui, Antonio Luis Carballo García, Ana Cristina Fernández Rísquez, Jesús Carlos Presa Lorite, Gabriel Fiol Ruiz","doi":"10.1089/aid.2024.0067","DOIUrl":"10.1089/aid.2024.0067","url":null,"abstract":"Infection with human immunodeficiency virus (HIV) shows a higher risk of infection by human papillomavirus (HPV). We aim to provide evidence about the effect of a Coriolus versicolor-based vaginal gel (Papilocare®) for treating HPV in women with HIV. Women ≥25 years coinfected by endocervical HPV and with low-grade abnormal cervicovaginal cytology were treated for 6 months with Papilocare in this observational, prospective, noncontrolled pilot study. Cytology, colposcopy, biopsy, hybrid capture test, and 5-point Likert scale were assessed to evaluate cervical lesions repair, HPV clearance, and changes in cervical reepithelization, respectively, at 6 months. Fifteen patients (25-54 years) were included. Overall HPV clearance and cytological normalization rates were 73.3% and 80.0%, respectively, and 55.6% of the abnormal colposcopies were normalized. Reepithelialization index improved in 66.7% of cases. Papilocare may be effective for managing endocervical HPV infection in patients living with HIV.","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"233-240"},"PeriodicalIF":1.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Dynamic Viral Rebound and Longitudinal Measures of Viral Load/CD4 Counts Among People with HIV in South Carolina. 动态病毒反弹与南卡罗来纳HIV感染者病毒载量/CD4计数纵向测量之间的关系

IF 1.5 4区医学

AIDS research and human retroviruses Pub Date : 2025-05-01 Epub Date: 2024-12-16 DOI: 10.1089/aid.2024.0035

Yunqing Ma, Jiajia Zhang, Jiayang Xiao, Xueying Yang, Sharon Weissman, Xiaoming Li, Bankole Olatosi

{"title":"Association Between Dynamic Viral Rebound and Longitudinal Measures of Viral Load/CD4 Counts Among People with HIV in South Carolina.","authors":"Yunqing Ma, Jiajia Zhang, Jiayang Xiao, Xueying Yang, Sharon Weissman, Xiaoming Li, Bankole Olatosi","doi":"10.1089/aid.2024.0035","DOIUrl":"10.1089/aid.2024.0035","url":null,"abstract":"Monitoring HIV viral rebound (VR) is crucial, as it indicates an increased risk of infection, transmission, disease progression, and drug resistance. This study aims to identify the association between dynamic VR and historical viral load (VL)/CD4 count measures. Fifteen-year South Carolina population-based electronic health record data were used for the study. VR was defined as the return of detectable levels of VL (>200 copies/mL) after stable viral suppression (VS) (two consecutive VS, i.e., VL ≤200 copies/mL). A generalized linear mixed model was used to evaluate the association between dynamic VR and historical time-dependent predictors, such as nadir CD4 count and comorbidities, within a year prior to each VR. Subgroup analysis for men who have sex with men (MSM) was also conducted. Among 8,185 people with HIV (PWH), 1,173 (14.3%) had a history of VR. Lower nadir CD4 count (≥500 vs. <200 cells/µL; adjusted odds ratio [aOR]: 0.51, 95% confidence interval [CI]: [0.43, 0.60]), younger age (>60 years old vs. 18-30 years old; aOR: 0.43, 95% CI: [0.29, 0.63]), and being Black (Black vs. White; aOR: 1.58, 95% CI: [1.34, 1.85]) were associated with a higher risk of VR, while MSM (MSM vs. heterosexual; aOR: 0.81, 95% CI: [0.67, 0.96]) were associated with decreased VR risk. The rate of VR among PWH in South Carolina is significant. Within-1-year VL/CD4 test is critical for identifying PWH at risk for VR. Tailored interventions are needed for PWH at risk for VR to achieve sustained suppression and better health outcomes.","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"253-262"},"PeriodicalIF":1.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0